Envestnet Asset Management Inc. Has $9.16 Million Stock Position in Exelixis, Inc. (NASDAQ:EXEL)

Envestnet Asset Management Inc. grew its stake in Exelixis, Inc. (NASDAQ:EXEL) by 23.9% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 248,073 shares of the biotechnology company’s stock after buying an additional 47,845 shares during the quarter. Envestnet Asset Management Inc. owned 0.09% of Exelixis worth $9,159,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in EXEL. Vanguard Group Inc. grew its position in Exelixis by 0.4% in the fourth quarter. Vanguard Group Inc. now owns 29,429,252 shares of the biotechnology company’s stock valued at $979,994,000 after purchasing an additional 121,750 shares in the last quarter. LSV Asset Management increased its position in shares of Exelixis by 0.8% during the 4th quarter. LSV Asset Management now owns 8,169,847 shares of the biotechnology company’s stock worth $272,056,000 after purchasing an additional 67,470 shares during the last quarter. Fuller & Thaler Asset Management Inc. raised its stake in shares of Exelixis by 10.2% during the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 7,630,940 shares of the biotechnology company’s stock worth $254,110,000 after purchasing an additional 708,312 shares in the last quarter. Invesco Ltd. boosted its holdings in shares of Exelixis by 308.1% in the 4th quarter. Invesco Ltd. now owns 3,975,241 shares of the biotechnology company’s stock valued at $132,376,000 after buying an additional 3,001,204 shares during the last quarter. Finally, AQR Capital Management LLC increased its holdings in Exelixis by 25.7% during the fourth quarter. AQR Capital Management LLC now owns 3,967,005 shares of the biotechnology company’s stock worth $132,101,000 after buying an additional 810,857 shares during the last quarter. Institutional investors own 85.27% of the company’s stock.

Exelixis Stock Performance

Shares of EXEL stock opened at $44.26 on Tuesday. The company has a market capitalization of $12.07 billion, a PE ratio of 20.12, a price-to-earnings-growth ratio of 0.89 and a beta of 0.28. Exelixis, Inc. has a 52-week low of $22.20 and a 52-week high of $49.62. The business’s fifty day moving average is $43.17 and its 200 day moving average is $38.47.

Insiders Place Their Bets

In related news, CMO Amy C. Peterson sold 72,776 shares of Exelixis stock in a transaction dated Friday, May 16th. The shares were sold at an average price of $45.47, for a total transaction of $3,309,124.72. Following the completion of the transaction, the chief marketing officer directly owned 465,393 shares of the company’s stock, valued at $21,161,419.71. This trade represents a 13.52% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Patrick J. Haley sold 34,387 shares of the company’s stock in a transaction that occurred on Tuesday, May 20th. The stock was sold at an average price of $44.06, for a total value of $1,515,091.22. Following the completion of the sale, the executive vice president owned 412,072 shares in the company, valued at $18,155,892.32. The trade was a 7.70% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 458,113 shares of company stock valued at $21,024,817 over the last three months. 2.85% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

EXEL has been the topic of several analyst reports. Royal Bank Of Canada reissued a “sector perform” rating and set a $50.00 target price (up from $45.00) on shares of Exelixis in a report on Tuesday, July 8th. JMP Securities lifted their target price on Exelixis from $47.00 to $50.00 and gave the company a “market outperform” rating in a research report on Monday, June 23rd. Jefferies Financial Group set a $50.00 price target on shares of Exelixis and gave the company a “buy” rating in a research note on Tuesday, June 24th. Stephens upgraded shares of Exelixis from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $29.00 to $60.00 in a research report on Tuesday, June 24th. Finally, Wells Fargo & Company restated a “market outperform” rating on shares of Exelixis in a research report on Thursday, April 17th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and thirteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $45.28.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.